EGFR and non-small cell lung carcinoma: From the limited clinical data, the alternative strategy between TKIs and cytotoxic chemotherapy is reasonable because the sensitivity of TKIs can be regained following a drug holiday for patients with NSCLC who initially responded to EGFR-TKIs treatment [18] and the EGFR mutation status was changed before and after TKIs treatment [19].